Next Article in Journal
Nerolidol and Farnesol Inhibit Some Cytochrome P450 Activities but Did Not Affect Other Xenobiotic-Metabolizing Enzymes in Rat and Human Hepatic Subcellular Fractions
Next Article in Special Issue
Synthesis, Characterization, Antimicrobial and Antiproliferative Activity Evaluation of Cu(II), Co(II), Zn(II), Ni(II) and Pt(II) Complexes with Isoniazid-Derived Compound
Previous Article in Journal
Revision of the Structure of Acremine P from a Marine-Derived Strain of Acremonium persicinum
Previous Article in Special Issue
Under-Reported Aspects of Platinum Drug Pharmacology
Article Menu
Issue 4 (April) cover image

Export Article

Open AccessReview
Molecules 2017, 22(4), 523;

Metal-Based PSMA Radioligands

Institute of Basic Medical Sciences, University of Oslo, Oslo 0372, Norway
Norwegian Medical Cyclotron Centre Ltd., P.O. Box 4950 Nydalen, Oslo 0424, Norway
Institute of Physics, University of Oslo, Oslo 0317, Norway
Author to whom correspondence should be addressed.
Academic Editors: Patrick Gamez and Ana B. Caballero
Received: 30 January 2017 / Revised: 13 March 2017 / Accepted: 18 March 2017 / Published: 24 March 2017
(This article belongs to the Special Issue Metal Based Drugs: Opportunities and Challenges)
Full-Text   |   PDF [5592 KB, uploaded 27 March 2017]   |  


Prostate cancer is one of the most common malignancies for which great progress has been made in identifying appropriate molecular targets that would enable efficient in vivo targeting for imaging and therapy. The type II integral membrane protein, prostate specific membrane antigen (PSMA) is overexpressed on prostate cancer cells in proportion to the stage and grade of the tumor progression, especially in androgen-independent, advanced and metastatic disease, rendering it a promising diagnostic and/or therapeutic target. From the perspective of nuclear medicine, PSMA-based radioligands may significantly impact the management of patients who suffer from prostate cancer. For that purpose, chelating-based PSMA-specific ligands have been labeled with various diagnostic and/or therapeutic radiometals for single-photon-emission tomography (SPECT), positron-emission-tomography (PET), radionuclide targeted therapy as well as intraoperative applications. This review focuses on the development and further applications of metal-based PSMA radioligands. View Full-Text
Keywords: prostate specific membrane antigen (PSMA); SPECT; PET; radionuclide therapy; intraoperative applications. prostate specific membrane antigen (PSMA); SPECT; PET; radionuclide therapy; intraoperative applications.

Figure 1

This is an open access article distributed under the Creative Commons Attribution License which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited (CC BY 4.0).

Share & Cite This Article

MDPI and ACS Style

Gourni, E.; Henriksen, G. Metal-Based PSMA Radioligands. Molecules 2017, 22, 523.

Show more citation formats Show less citations formats

Note that from the first issue of 2016, MDPI journals use article numbers instead of page numbers. See further details here.

Related Articles

Article Metrics

Article Access Statistics



[Return to top]
Molecules EISSN 1420-3049 Published by MDPI AG, Basel, Switzerland RSS E-Mail Table of Contents Alert
Back to Top